BETA: Please send your feedback!
Exelixis
EXEL:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
About
Biotechnology
Founded 1994
Exelixis, Inc. is a biopharmaceutical company. It engages in the developing and commercializing small molecule therapies for the treatment of cancer. The company brands include comertriq and cobimetinib. Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Peter Lamb, PhD | Chief Scientific Officer & Executive VP | Male |
| Gisela M. Schwab, MD | Chief Medical Officer & President-Medical Affairs | null |
| Stelios B. Papadopoulos, PhD, MBA | Chairman | Male |
| Michael M. Morrissey, PhD | President, Chief Executive Officer & Director | Male |
| Corey S. Goodman, PhD | Founder | Male |
| Susan Hubbard | EVP-Public Affairs & Investor Relations | Female |
| Laura Dillard | Vice President-Human Resources | Female |
| Jeffrey J. Hessekiel | Secretary, Executive VP & General Counsel | Male |
| Christopher J. Senner, CPA | Executive VP, Chief Financial & Accounting Officer | Male |
| William Berg, PhD | Senior Vice President-Medical Affairs | Male |
Mindful Investing Summary
Exelixis - Competitors and Related Companies
How Exelixis stacks up to its peers in the Biotechnology industry or with competing business segments.
Exelixis
EXEL:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2021
—
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
Pfizer
PFE:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
Sanofi
SAN-FR:PAR
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
ArQule
ARQL:NAS
Pharmaceuticals: Other
—
MICRO cap
(—)
—
since start of 2021
—
Curis
CRIS:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2021
—